Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
UConn Health
With
Novartis
This study will assess whether aliskiren will lower clinic blood pressure and 24-hour blood pressure in patients with hypertension and vitamin D deficiency. Additionally, this study will further explore the potential additional effects of adding vitamin D to aliskiren in this patient population.
Age
21–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Men or women over 21 years of age with a history of Stage 1 or 2 hypertension (defined as a seated diastolic BP ≥ 90 mmHg and \< 110 mmHg in the untreated state).
Patients under treatment for hypertension must be willing and able to discontinue any previous antihypertensive medications for the duration of the study.
25-hydroxyvitamin D levels \< 30 ng/ml and \> 12 ng/ml.
Women of childbearing potential must be using a medically acceptable form of birth control for the duration of the trial, must have a negative serum pregnancy test at screening, and must have a negative urine pregnancy test within 7 days before initiating aliskiren therapy.
You may not be if
Vitamin D levels \< 12 ng/ml
Known hypersensitivity or allergy to aliskiren
Clinic blood pressure \> 180/110 mmHg
Known forms of secondary hypertension
Chronic atrial fibrillation
Uncontrolled or unstable cardiovascular diseases
Shift or night workers
Mid-arm circumference \> 42 cm in diameter
Current or recent (\<1 year) alcohol or drug abuse
Pregnant or lactating women
Clareo Health | Vitamin D Deficiency in Patients With Hypertension
